Omnicell Inc (FRA:OC9) Stock Price, Trades & News

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Financial Strength

6/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	1.26
Equity-to-Asset	0.63
Debt-to-Equity	0.16
Debt-to-EBITDA	1.7
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.74	Distress Grey Safe
Beneish M-Score	-2.74	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-3.3
	3-Year EBITDA Growth Rate	-2.1
	3-Year EPS without NRI Growth Rate	-18.6
	3-Year FCF Growth Rate	59.2
	3-Year Book Growth Rate	2.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	12.48
	Future 3-5Y Total Revenue Growth Rate Estimate	5.29

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	71.72
	9-Day RSI	69.52
	14-Day RSI	64.71
	3-1 Month Momentum %	21.19
	6-1 Month Momentum %	-14.88
	12-1 Month Momentum %	46.4

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.5
	Quick Ratio	1.29
	Cash Ratio	0.53
	Days Inventory	53.2
	Days Sales Outstanding	71.31
	Days Payable	29.58

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.2
	Shareholder Yield %	12.19

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	43.5
	Operating Margin %	2.75
	Net Margin %	1.67
	EBITDA Margin %	9.71
	FCF Margin %	8.01
	OCF Margin %	12.75
	ROE %	1.64
	ROA %	1
	ROIC %	1.08
	ROC (Joel Greenblatt) %	21.1
	ROCE %	2.21
	Years of Profitability over Past 10-Year	9
	Moat Score	5
	Tariff Resilience Score	7

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	102.5
	Forward PE Ratio	22.57
	PE Ratio without NRI	23.61
	Shiller PE Ratio	64.99
	Price-to-Owner-Earnings	36.67
	PS Ratio	1.7
	PB Ratio	1.63
	Price-to-Tangible-Book	6.81
	Price-to-Free-Cash-Flow	21.26
	Price-to-Operating-Cash-Flow	13.35
	EV-to-EBIT	60.47
	EV-to-EBITDA	17.1
	EV-to-Forward-EBITDA	13.43
	EV-to-Revenue	1.66
	EV-to-Forward-Revenue	3.69
	EV-to-FCF	20.44
	Price-to-GF-Value	1.16
	Price-to-Projected-FCF	1.01
	Price-to-Median-PS-Value	0.65
	Price-to-Graham-Number	2.68
	Earnings Yield (Greenblatt) %	1.65
	FCF Yield %	4.69
	Forward Rate of Return (Yacktman) %	-6.66

Financials (Next Earnings Date:2026-07-31 Est.)

Annual Quarterly TTM

FRA:OC9's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Omnicell Inc Operating Data

Annual Quarterly

FRA:OC9's Complete Operating Data

No operating data available for Omnicell Inc.

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Omnicell Inc Executives

Details

GF Value™: €33.35

FRA:OC9

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with OC9. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	1,052.763
	EPS (TTM) (€)	0.379
	Beta	1.9011
	3-Year Sharpe Ratio	-0.19
	3-Year Sortino Ratio	-0.3
	Volatility %	46.84
	14-Day RSI	64.71
	14-Day ATR (€)	0.870056
	20-Day SMA (€)	34.99
	12-1 Month Momentum %	46.4
	52-Week Range (€)	22.8 - 43.8
	Shares Outstanding (Mil)	45.48

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Omnicell Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Omnicell Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-30 08:30	In 113 days
Third quarter earnings results for 2026	2026-10-30	In 112 days
Second quarter earnings conference call for 2026	2026-07-31 08:30	In 22 days
Second quarter earnings results for 2026	2026-07-31	In 21 days
Guidance call for 2026	2026-06-09 15:20	36.60 (+0.00%)
General meeting for 2026	2026-05-19 16:30	37.20 (+2.76%)
Guidance call for 2026	2026-05-12 08:40	36.40 (-0.55%)
First quarter earnings conference call for 2026	2026-04-28 08:30	32.00 (+2.56%)
First quarter earnings results for 2026	2026-04-28	32.00 (+2.56%)
Annual report for 2025	2026-02-26	34.80 (+3.57%)

Show

Entries

Omnicell Inc Frequently Asked Questions

What is Omnicell Inc(FRA:OC9)'s stock price today?

The current price of FRA:OC9 is €38.80. The 52 week high of FRA:OC9 is €43.80 and 52 week low is €22.80.

When is next earnings date of Omnicell Inc(FRA:OC9)?

The next earnings date of Omnicell Inc(FRA:OC9) is 2026-07-31 Est..

Does Omnicell Inc(FRA:OC9) pay dividends? If so, how much?

Omnicell Inc(FRA:OC9) does not pay dividend.

Press Release

	Subject	Date
	Nnamdi Njoku Appointed President of Omnicell	2026-07-01
	Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business	2026-06-08
	Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026	2026-06-02
	Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer	2026-04-29
	Omnicell Announces First Quarter 2026 Financial Results	2026-04-28
	Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026	2026-04-13
	Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026	2026-01-13
	Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management	2025-12-08
	Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference	2025-11-20
	Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies	2025-11-13

10/Page

Articles on Omnicell Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.